<DOC>
	<DOCNO>NCT02357030</DOCNO>
	<brief_summary>The Gulf War Synergy Trial evaluate safety efficacy currently available medication , methylphenidate ( Ritalin® ) , combine GWI Nutrient Formula ( K-PAX Synergy ) treat Gulf War Illness ( GWI ) .</brief_summary>
	<brief_title>Methylphenidate Plus GWI-Nutrient Formula Treatment Patients With Gulf War Illness</brief_title>
	<detailed_description>This trial evaluate safety efficacy currently available medication , methylphenidate ( Ritalin® ) , combine mitochondrial support nutrient formula ( K-PAX Synergy ) treat Gulf War Illness ( GWI ) . The nutrient formula use trial broad-spectrum micronutrient supplement . This nutrient formula provide GWI patient vitamin , mineral , cofactor ( amino acid , antioxidant , mitochondrial cofactor ) complement low-dose Central Nervous System ( CNS ) stimulant ( methylphenidate ) . The low-dose CNS stimulant provide necessary catalyst augment metabolism cellular fuel production cellular energy.Therapeutic dosage micronutrient provide support function nervous , endocrine , immune system level low customary dosage methylphenidate produce positive clinical effect GWI symptom also well tolerate without deplete degrade system . The dose methylphenidate ( Ritalin® ) test study relatively low ( 5-10mg twice daily ) . This drug clinical use 50 year treatment Narcolepsy Attention Deficit Disorder well-described safety profile use recommend . GWI Chronic Fatigue Syndrome ( CFS ) share high degree symptom overlap . They link mitochondrial dysfunction . Methylphenidate alone study treatment CFS past show produce mild benefit well-tolerated . When provided innovative therapy , methylphenidate plus CFS Nutrient Formula produce substantial improvement CFS symptom limit number patient , demonstrate excellent tolerability . Use low dose methylphenidate coadministered mitochondrion support nutrient formula previously evaluate controlled clinical study . The risk patient use combination believe low , especially context well-controlled clinical study . Furthermore , combination expect increase incidence severity adverse event associate methylphenidate .</detailed_description>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>1 . Male female patient age 18 64 , inclusive time inform consent 2 . Patients currently meet Kansas Case Definition GWI 3 . Patients otherwise good health base medical history screen evaluation determine Investigator ( see specific exclusion criterion ) 4 . Willingness take multivitamin , nutritional herbal supplement study treatment course trial ; least one week washout current nutritional supplement require screen baseline visit . Nutritional supplement exempt requirement limit follow ( exemption require waiver Medical Monitor ) : 1 . Probiotic supplement ( L. acidophilus , Bifidobacterium , etc . ) 2 . Fiber supplement 3 . Fish oil supplement 4 . Digestive enzymes 5 . Melatonin &lt; 10mg per day 6 . Calcium &lt; 600mg per day 7 . Magnesium &lt; 400mg per day 8 . Vitamin D &lt; 400 i.u . per day 5 . Willingness consume caffeinecontaining supplement study period ( coffee , tea chocolate exempt ) . These supplement include limited following : 1 . Red Bull® 2 . Monster® 3 . Rockstar® 4 . 5hour® energy shot 6 . Willingness consume prescription stimulant ( i.e . Provigil® , Nuvigil® , Adderall® , Ritalin® , amphetamine ) study period . 7 . Willingness consume pseudoephedrinecontaining product study period . 8 . Willingness female practice effective contraception . 1 . Pregnancy lactation 2 . Active substance alcohol abuse and/or history prescription stimulant abuse 3 . Hospitalization within past five year follow : 1 . Active substance alcohol abuse and/or history prescription stimulant abuse 2 . Major Depressive Disorder ( MDD ) 3 . Post Traumatic Stress Disorder ( PTSD ) 4 . Previous current diagnosis schizophrenia bipolar disorder 5 . Currently take prescription medication treat anxiety daily basis 6 . Use medication 3 time per week within past 3 month : 1 . MAO inhibitor 2 . Antipsychotic medication 3 . Prescription stimulant ( i.e . Provigil® , Nuvigil® , Adderall® , Ritalin® , amphetamine ) 4 . Coumarin anticoagulant ( Coumadin® ) 7 . Daily concurrent use one antidepressant medication except one two antidepressant medication one follow ( unless specifically grant waiver Medical Monitor ) : 1 . Amitriptyline ≤ 100 qhs 2 . Trazodone ≤ 100 qhs 3 . Doxepin ≤ 50 qhs 8 . Active medical condition include : 1 . Glaucoma 2 . Diabetes mellitus 3 . Current stomach duodenal ulcer 4 . Uncontrolled hypertension ( blood pressure screen systolic &gt; 160 diastolic &gt; 90 ) 5 . Heart disease ( include history cardiac arrhythmia , cardiac ischemia , syndrome Torsade de Pointes , myocardial infarction cerebrovascular event ) 6 . Motor tics diagnosis family history Tourette 's syndrome 7 . Previous history seizure 8 . A diagnosis follow condition : Cancer ( receive systemic treatment either currently within past 12 month ) Chronic Renal Disease Chronic Liver Disease HIV Infection Chronic Hepatitis B C Systemic Lupus Erythematosus Multiple Sclerosis Rheumatoid Arthritis Parkinson 's Disease Amyotrophic Lateral Sclerosis ( ALS ) Any chronic infectious disease last six month longer 9 . Clinically significant laboratory test value determine Medical Monitor 10 . Clinically significant ECG abnormality determine Medical Monitor 11 . The take another investigational treatment either currently within 30 day screen visit 12 . Compliance criterion : A subject eligible he/she , opinion Investigator , unable comply aspect study protocol , include visit schedule .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Gulf War Illness</keyword>
	<keyword>nutrient</keyword>
	<keyword>methylphenidate</keyword>
	<keyword>mitochondrion</keyword>
</DOC>